Log in
|
Specification |
Details |
|
Drug Detected |
Methylphenidate (MPD) |
|
Common Brand Name |
Ritalin®* (registered Trade Mark from Novartis) |
|
Cutoff Level |
300 ng/mL |
|
Sample Type |
Human Urine |
|
Test Format |
Rapid Test Strip |
|
Time to Results |
Approximately 5 Minutes |
|
Accuracy |
Up to 99% |
|
Intended Use |
Professional & Forensic Use Only |
Using the test strip is quick and straightforward:
Remove the test strip from its sealed pouch and use it immediately.
Hold the strip by the labeled end and avoid touching the test membrane.
Dip the test strip vertically into the urine specimen for 10–15 seconds, ensuring the urine level does not exceed the MAX line.
Remove the strip and place it on a clean, flat, non-absorbent surface.
Allow the test to develop and read the results within 3–5 minutes. Do not interpret results after 10 minutes.
Following the recommended testing procedure helps ensure reliable and accurate preliminary screening results
Methylphenidate (MPD) is a prescription central nervous system (CNS) stimulant commonly used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. It works by increasing the activity of certain neurotransmitters in the brain, helping improve attention, focus, and impulse control in patients with ADHD.
Methylphenidate is marketed under several brand names, including Ritalin®, Concerta®, Daytrana®, Metadate®, and others. Because it is a controlled prescription medication with the potential for misuse, professional drug testing may be required in clinical, workplace, and forensic settings
When prescribed and taken under medical supervision, methylphenidate is used for:
Attention-Deficit/Hyperactivity Disorder (ADHD)
Narcolepsy
Improving attention and concentration
Reducing impulsive behavior
Supporting long-term ADHD management
Methylphenidate
Although methylphenidate is an effective prescription medication, it may also be misused for its stimulant effects. Non-medical use can involve taking higher-than-prescribed doses or using the medication without a prescription.
Professional drug screening helps identify possible methylphenidate exposure in:
Workplace drug testing
Compliance monitoring
Treatment and rehabilitation programs
Forensic investigations
Court-ordered testing
Healthcare monitoring
When used as prescribed, methylphenidate may help improve concentration and reduce symptoms of ADHD. Possible effects may include:
Improved attention and focus
Increased alertness
Better concentration
Reduced hyperactivity
Increased energy
Elevated heart rate
Increased blood pressure
Reduced appetite
Difficulty sleeping (insomnia)
Methylphenidate is available under several prescription brand names, including:
Ritalin
Concerta
Metadate
Daytrana
Aptensio XR
Jornay PM
Quillivant XR
Quillichew ER
The Ritalin Drug Test Strip (MPD) offers several advantages for professional drug screening:
Rapid preliminary results in approximately 5 minutes
Up to 99% accuracy
300 ng/mL screening cutoff
Substance-specific methylphenidate detection
Simple dip-and-read procedure
No laboratory equipment required
Easy interpretation of results
Suitable for routine and high-volume testing
Designed for professional and forensic environments
For reliable performance:
Store the test strips according to the recommended storage conditions.
Keep each strip sealed in its original pouch until ready for use.
Use the strip immediately after opening the pouch.
Do not use the product after its expiration date.
Protect the test from excessive heat, humidity, and direct sunlight.
Handle urine specimens using appropriate laboratory safety procedures
The Ritalin Drug Test Strip (MPD) provides preliminary qualitative screening results only.
A positive result indicates the possible presence of methylphenidate (MPD) above the screening cutoff but does not determine the amount consumed, frequency of use, or level of impairment.
A negative result does not necessarily exclude methylphenidate use if the concentration is below the cutoff level or outside the detection window.
Individual metabolism, specimen quality, hydration status, collection procedures, and testing conditions may influence results.
Any preliminary positive result should be confirmed using Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) before legal, employment, medical, or administrative decisions are made
The Ritalin Drug Test Strip (MPD) is designed to detect methylphenidate (MPD) in human urine.
This test uses a 300 ng/mL cutoff level for detecting methylphenidate.
Results are available in approximately 5 minutes when the testing instructions are followed correctly.
Yes. The Ritalin Drug Test Strip (MPD) is suitable for professional drug screening in workplaces, treatment centers, healthcare facilities, compliance programs, and forensic laboratories.
No. The test only detects the presence of methylphenidate above the screening cutoff. It cannot determine whether the medication was used as prescribed or misused. Clinical evaluation and professional judgment are required when interpreting results.
No. This product is intended for professional and forensic use only and is not intended for medical or diagnostic purposes
The Ritalin Drug Test Strip (MPD) provides a fast, accurate, and reliable solution for the preliminary detection of methylphenidate (MPD) in human urine. Featuring up to 99% accuracy, a 300 ng/mL cutoff level, and results in approximately 5 minutes, this professional test strip offers dependable performance for routine and high-volume drug screening.
The simple dip-and-read format eliminates the need for specialized laboratory equipment or technical training, making the test suitable for clinical monitoring, workplace drug testing, treatment and rehabilitation centers, compliance programs, healthcare facilities, law enforcement agencies, and forensic laboratories. Its rapid turnaround time, ease of use, and substance-specific detection make it an effective solution for professional methylphenidate screening.
As with all rapid immunoassay screening devices, any preliminary positive result should be confirmed using Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) before legal, employment, medical, or administrative decisions are made. The Ritalin Drug Test Strip (MPD) is intended for professional and forensic use only and is not intended for medical diagnosis or home use.
The Methylphenidate Drug Test Strip (MPD) is a rapid urine screening device designed for the qualitative detection of methylphenidate (MPD) in human urine. Using a simple dip-and-read format, this professional test strip delivers preliminary results in approximately 5 minutes, making it an efficient solution for routine and high-volume drug screening.
Designed with a 300 ng/mL cutoff level, the Ritalin Drug Test Strip provides dependable preliminary screening with up to 99% accuracy. Its substance-specific design allows for reliable detection of methylphenidate without the need for laboratory equipment or specialized training.
The easy-to-use test strip is ideal for clinical monitoring, compliance testing, forensic laboratories, rehabilitation centers, workplace drug testing, and other professional screening environments. Its compact design and rapid turnaround time make it suitable for fast, on-site testing.
The Ritalin Drug Test Strip (MPD) provides preliminary qualitative screening results only. Any preliminary positive result should be confirmed using a more specific laboratory confirmation method such as Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS).
This product is intended for professional and forensic use only and is not intended for medical diagnosis
Methylphenidate (MPD)
Methylphenidate is generally detectable in urine for approximately 1–3 days after use. Detection time may vary depending on dosage, frequency of use, metabolism, hydration, and individual health factors.
Longer detection periods may occur in some individuals depending on testing conditions
This Ritalin Drug Test Strip (MPD) uses a screening cutoff of:
Methylphenidate (MPD): 300 ng/mL
Samples at or above this concentration may produce a preliminary positive result and should be confirmed using an appropriate laboratory confirmation method
A colored line appears in both the Control (C) and Test (T) regions. Even if the Test (T) line appears faint, the result should be interpreted as negative, indicating that the concentration of methylphenidate (MPD) is below the 300 ng/mL cutoff level
A colored line appears only in the Control (C) region, while no visible line appears in the Test (T) region. This indicates that methylphenidate (MPD) may be present at or above the 300 ng/mL screening cutoff.
Because this device provides preliminary screening results only, all positive results should be confirmed using a more specific laboratory confirmation method such as Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
If the Control (C) line does not appear, the test result is invalid, regardless of whether a Test line is visible. This may occur due to insufficient specimen volume, improper testing procedure, or a defective test strip.
Repeat the test using a new strip and a fresh urine specimen
Methylphenidate MPD Drug Test Strip 300 ng/mL | Serenity | Methylphenidate (MPD) | SM-DOA-MPDSCN 25/Box
Sign up for updates from leading retailers
